Item 5.02 Election of Directors; Appointment of Certain Officers.
On September 10, 2020, GW Pharmaceuticals plc (the "Company") announced that
David Gryska has been appointed by its Board of Directors (the "Board") to join
the Board. In connection with his appointment to the Board, Mr. Gryska was also
appointed to the Audit Committee of the Board.
Mr. Gryska has years of experience as Chief Financial Officer at Incyte
Corporation, Celgene Corporation, Scios, Inc., and Cardiac Pathways Corporation
and is currently on the boards of Seattle Genetics, Inc., PDL BioPharma, Inc.,
and Aerie Pharmaceuticals, Inc.
There are no arrangements or understandings between Mr. Gryska and any other
persons pursuant to which he was selected to serve as a director the Company. In
addition, there are no transactions between the Company and Mr. Gryska or his
immediate family members requiring disclosure under Item 404(a) of Regulation
S-K promulgated under the Securities Act of 1933, as amended. The Board has
determined that Mr. Gryska meets the independence requirements of Rule 10A-3
under the Securities Exchange Act of 1934, as amended and the applicable Nasdaq
rules. Mr. Gryska's compensation for his services as a director will be
consistent with that of the other non-employee directors of the Company, as
described in the Company's definitive proxy statement with respect to its 2020
Annual Meeting of Shareholders, filed with the Securities and Exchange
Commission on April 7, 2020.
On September 10, 2020, the Company issued a press release announcing
Mr. Gryska's appointment to the Board. A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated herein by this reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Number Description
99.1 Press release dated September 10, 2020.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
GW PHARMACEUTICALS PLC 
